CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become a standard-of-care treatment for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and B-cell lineage acute lymphoblastic leukemia (B-ALL). Here, CD19 is linked to diffuse large B-cell lymphoma.